Quick Answer
GUIDED THERAPEUTICS INC reported Long Term Debt of $0.00 for the year ending 2022.
- GUIDED THERAPEUTICS INC showed a decrease of -100.0% in Long Term Debt from 2021 to 2022.
- This data is from GUIDED THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 30, 2023.
- XBRL data for this metric is available from 2010 to 2022 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $17.0 thousand | Q4 2011: $4.0 thousand | Q4 2012: $2.35 million | Q4 2012: $0.00 | Q1 2013: $1.72 million | Q2 2013: $157.0 thousand | Q2 2013: $2.65 million | Q3 2013: $135.0 thousand | Q4 2013: $103.0 thousand | Q1 2014: $99.0 thousand | Q2 2014: $4.0 thousand | Q3 2014: $40.0 thousand | Q4 2014: $40.0 thousand | Q2 2015: $1.03 million | Q3 2015: $0.00 | Q2 2020: $50.0 thousand | Q4 2020: $23.0 thousand | Q1 2021: $6.0 thousand | Q2 2021: $755.0 thousand | Q3 2021: $787.0 thousand | Q4 2021: $22.0 thousand | Q1 2022: $0.00 | Q2 2022: $0.00 | Q3 2022: $0.00.
- Over the full 11 years of available data (2010 to 2022), GUIDED THERAPEUTICS INC's Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2022: $0.00 | Fiscal year 2021: $22.0 thousand | Fiscal year 2021: $820.0 thousand | Fiscal year 2020: $23.0 thousand | Fiscal year 2020: $23.0 thousand | Fiscal year 2019: $0.00 | Fiscal year 2019: $5.71 million | Fiscal year 2018: $5.07 million | Fiscal year 2017: $7.96 million | Fiscal year 2011: $4.0 thousand | Fiscal year 2010: $31.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: